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1  | INTRODUC TION
Influenza is a disease with high morbidity and mortality which is 
caused by influenza viruses of types A and B.1,2 Seasonal influenza 
epidemics are estimated to result in 3‐5 million cases of severe ill‐
ness and about 290 000‐650 000 respiratory deaths worldwide.2
2  | SECRETORY IGA PRODUC TION UPON 
NATUR AL INFLUENZ A INFEC TION
Influenza viruses infect humans through the mucosal epithelium 
covering the upper respiratory tract; thus, the respiratory epithelium 
constitutes the site of virus entry, infection, and host immune re‐
sponse (Figure 1). Antibodies located on the surface of the mucosa 
represent the major immune components providing protection 
against influenza. Upon infection, the human humoral immune re‐
sponse is activated leading principally to the production of local se‐
cretory IgA (sIgA) in the mucosa of the upper respiratory system, 
serum IgA and IgG antibodies.3
2.1 | Role of IgA and IgG antibodies
Whereas sIgA antibodies have the role to neutralize potential 
pathogens at the entrance site before they could attach epithelial 
cells and overcome the epithelium surface, serum IgA represent 
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Abstract
Secretory IgAs (sIgA) constitute the principal isotype of antibodies present in nasal 
and mucosal secretions. They are secreted by plasma cells adjacent to the mucosal 
epithelial cells, the site where infection occurs, and are the main humoral mediator 
of	mucosal	immunity.	Mucosally	delivered	vaccines,	such	as	live	attenuated	influenza	
vaccine (LAIV), are able to mimic natural infection without causing disease or virus 
transmission and mainly elicit a local immune response. The measurement of sIgA 
concentrations in nasal swab/wash and saliva samples is therefore a valuable tool 
for evaluating their role in the effectiveness of such vaccines. Here, we describe two 
standardized assays (enzyme‐linked immunosorbent assay and microneutralization) 
available	for	the	quantification	of	sIgA	and	discuss	the	advantages	and	limitations	of	
their use.
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“backup” antibodies whose function is to respond in case of sys‐
temic infection due to invasion across the mucosal epithelium.4 
IgG‐secreting cells are produced in the mucosa‐associated lym‐
phoid	tissues	(MALTs)	and	regional	lymph	nodes.	IgG	antibodies	
are secreted in the bloodstream and, reached the mucosal tis‐
sues, move via diffusion from the serum to the mucus.5 IgA is 
characterized by an elevated ability in preventing virus infection, 
whereas IgG exerts only a marginal role in providing protec‐
tion toward infections affecting the upper respiratory system. 
However, IgG antibodies are principally involved in reducing viral 
pneumonia.6
2.2 | Role of cellular immune responses
Along with the humoral immunity, also the cell‐mediated immune 
(CMI)	response	is	activated	after	influenza	infection.	Unlike	humoral	
response,	 capable	 of	 neutralizing	 activity,	 CMI	 is	 able	 to	 prevent	
virus replication and decrease the time for recovery.7,8 CD4+ follicu‐
lar helper T (Th) lymphocytes in presence of antigen‐presenting cells 
(APCs), such as dendritic cells (DCs) and influenza antigens, induce 
the differentiation of naïve B cells into IgA‐secreting plasma cells 
(PCs). sIgA constitute the principal isotype of antibodies present in 
external secretions, such as nasal fluid, saliva, milk, colostrum intes‐
tinal fluid, and gallbladder bile.9 In the upper respiratory tract, sIgA 
antibodies are secreted by mucosal PCs adjacent to the mucosal epi‐
thelial layer at the site of infection10 and represent the main humoral 
mediator of nasal immunity.11
2.3 | Immune mechanisms contributing to disease 
reduction or protection
In influenza‐naive subjects, the clearance of primary viral infection 
occurs	through	sIgA	and	cytotoxic	T	lymphocytes	(CTLs).	More	spe‐
cifically, sIgA appear on day 5 post‐infection, and their level rapidly 
increases in the nasal wash until day 7‐10 post‐infection, when it 
reaches a plateau. IgA local immune response persists for a period 
of 3‐5 months5,12,13 and then gradually diminishes returning to the 
pre‐immunization levels within 6 months.14 In addition, it is possi‐
ble to detect IgA‐producing memory cells locally.5,12,13 CTLs appear 
transiently in the nasal mucosa and peak on day 7 after infection. 
sIgA have a pivotal role in protecting against influenza infection of 
the upper respiratory mucosal surfaces, since they can disarm the 
virus either before it crosses the mucosal barrier15 or in infected 
epithelial cells by intracellular neutralization.15,16 The magnitude 
of the IgA antibody response is directly correlated with resistance 
to new infections.17 In addition, IgA is the predominant Ig isotype 
in local secretions after secondary infection and an IgA response is 
also	detected	 in	 the	 serum	upon	subsequent	 infection	which	 sup‐
port its additional important role in protection against influenza 
virus re‐infections.18
Along	with	IgA,	IgM	antibodies	are	also	secreted	actively	across	
the mucosa and may contribute to protection by preventing viral 
entry into the cells and also interfering with virus replication in 
the cells.5,18	The	potential	protective	role	of	IgM	antibodies	is	sup‐
ported	by	a	study	in	mice	which	has	shown	that	IgM	antibodies	can	
F I G U R E  1   Simplified scheme of immune responses following influenza virus infection of the upper respiratory tract with focus on 
induction and mode of action of secreted IgA (sIgA). Abbreviations: B cell, B lymphocyte; DCs, dendritic cells; dIgA, dimeric IgA; IgA, 
immunoglobulin	A;	IgG,	immunoglobulin	G;	MALT,	mucosa‐associated	lymphoid	tissue;	PCs,	plasma	cells;	pIgR,	polymeric	immunoglobulin	
receptor	(pIgR);	T	cell,	T	lymphocyte.	Influenza	viruses	infect	epithelial	cells	of	the	mucosa	and	induce	mucosal	immune	responses.	Mucosal	
immune	system	consists	of	two	sites.	Inductive	site	(MALT)	for	antigen	uptake	by	DCs	and	priming	of	T	and	B	cells	for	IgA	antibody	
production. Effector site with IgA‐secreting PCs. DCs take up exogenous virus antigens (from virus particles or apoptotic infected cells) by 
endocytosis and activate naïve T and B cells. PCs secrete IgA antibodies. IgG antibodies transude from the serum to the mucus by diffusion 
and provide protection against homologous influenza viruses. dIgA are actively transcytosed across epithelial cells via pIgR and provide 
protection against homologous and heterologous influenza viruses. dIgA can bind to newly synthesized viral proteins within virus‐infected 
epithelial cells and prevent virus
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neutralize influenza viruses in the presence of complement just as 
well as IgG antibodies.19
2.4 | IgA immune responses upon influenza virus 
infection of the mucosa of the upper respiratory tract
On the basolateral surface of the epithelial cells in the lamina propria 
of mucosal tissue, a polymeric Ig receptor (pIgR) links the dimeric 
IgA (dIgA) and moves to the apical side (Figure 1). During the pro‐
cess of transcytosis across the epithelial cells, polymeric IgA (pIgA) 
acquires	 the	secretory	component	 (SC),	producing	sIgA.	Secretory	
component is an unusual extra polypeptide that constitutes the ex‐
tracellular portion of pIgR upon cleavage by a selective protease.20 
The presence of SC provides sIgA a greater functional stability, both 
by masking the protease sites from proteolytic degradation operated 
by proteases present in mucosal secretions21 and by sustaining the 
association of monomeric IgA (mIgA).22
IgA do not promote the activation of the inflammatory comple‐
ment system, a feature which is critical to maintaining the integrity 
of the mucosal barrier.23
2.5 | Presentation forms and functions of 
IgA antibodies
In human serum, IgA are mainly present in the monomeric form with 
two α‐heavy and two light chains. On the other hand, in external 
secretions	IgA	are	highly	heterogeneous	in	terms	of	their	quaternary	
structure but the majority are in polymeric form.24 sIgA are generally 
present	as	a	dimer,	despite,	and	at	low	frequency,	as	larger	polymeric	
forms (pIgA) especially tetramers.25
It has been hypothesized that pIgA may have a higher ability 
than mIgA to neutralize intracellular viral particle assembly by 
binding newly synthesized viral proteins.5,17,26 It has also been 
demonstrated that the polymeric nature of sIgA was responsible 
for their elevated cross‐reactivity, thereby increasing the avid‐
ity of this antibody subclass in comparison with mIgA and serum 
IgG.27,28
The best neutralizing activity and the higher avidity of human 
pIgA than mIgA can be attributed to the presence of multiple 
antigen‐binding sites located on each Ig polymer, indicating that 
the	quaternary	structure	plays	a	key	role	for	their	potency.25 This 
result is in accordance with previous researches conducted on 
mice.27,29,30 A recent study by Saito and colleagues demonstrated 
that IgA tetramerization improves target breadth exerting no ef‐
fect on potency of functionality of anti‐influenza virus broadly 
neutralizing antibody.31 The higher anti‐viral activity of pIgA than 
mIgA is particularly important, considering the anatomical site of 
sIgA action.10 pIgA appears to have a greater inhibitory potential 
in preventing viral attachment and virus neutralization than mIgA 
and also IgG.29,32,33 Another study showed the existence of larger 
pIgA in addition to tetrameric sIgA in the upper respiratory tract. 
The proportion of this polymeric form is approximately 20% of the 
total IgA.34
In summary, the mucosal surface is endowed with two protective 
barriers against viral infection, both of which involve mucosal IgA, 
that is, extracellular sIgA and intracellular pIgA.29
3  | IGA IMMUNE RESPONSE UPON 
INFLUENZ A VACCINATION
Conventional inactivated influenza vaccines (IIVs), generally deliv‐
ered through subcutaneous or intramuscular injection, are today still 
the most efficient, valuable, and low‐cost tools to effectively reduce 
influenza	virus	 infections	 and	 subsequently	morbidity	 and	mortal‐
ity.35 This parental administration is able to increase the serum an‐
tibody level in the systemic immune compartment, but it is not able 
to trigger a local mucosal immune response at the site of primary in‐
fection, that is, an induction of sIgA which exhibit a wide cross‐pro‐
tection activity. This represents a limit for conventional inactivated 
influenza vaccines in conferring full protection against infection.36
While natural infection is able to induce both mucosal and sys‐
temic heterosubtypic responses, the immunity induced by parenter‐
ally application of inactivated influenza vaccines is generally virus 
subtype‐specific.37 In pre‐immunized subjects, the natural contact 
with the pathogen causes a rapid synthesis of IgA and IgG by B mem‐
ory cells already 3 days after infection. These immunoglobulins form 
Ig‐virus complexes which result in virus inactivation.17
In recent years, an increasing number of pre‐clinical and clinical 
studies have been performed which have led to a better understand‐
ing how mucosal antibodies could be elicited by intranasal vaccina‐
tion with live attenuated influenza vaccines (LAIV). Live attenuated 
influenza vaccines is administered as a nasal spray and contains a 
cold‐adapted (ca) live attenuated influenza virus which, in contrast 
to wild‐type viruses, is able to replicate well at lower temperatures 
(around 25°C) and as such only in the upper respiratory tract, but 
not at higher temperatures (37°C) which does not allow replication 
in the lower respiratory tract including the lungs. Such property 
does not allow the ca virus to replicate in lung tissues or cause the 
onset of influenza‐like illness.38 LAIVs have been introduced firstly 
by Russia.39 They have been used in adults since the 1950s, and 
from 1987 onwards, the use of Russian LAIV for the prophylaxis of 
influenza has been widely extended to all age groups including chil‐
dren aged over 3 years.40 LAIVs have been licensed in the Unites 
States (US) in 2003 for healthy subjects aged 2‐49 years and in the 
European Union (EU) in 2012 for healthy children aged 2‐17 years.41 
Whereas some countries, including Russia, have licensed only triva‐
lent	LAIVs	(T‐LAIVs),	recently	a	quadrivalent	LAIV	(Q‐LAIV)	vaccine	
(MedImmune/AstraZeneca)	has	been	introduced	in	other	countries,	
such as the US (since 2012), Canada (since 2013), and EU (since 
2015),	under	the	trade	names	FluMist™	in	the	US	and	Canada,	and	
FluenzR in the EU.42
Studies performed in mice have demonstrated the predom‐
inant protective role played by sIgA,43,44 even in case of absence 
of T cells.45 Specifically, the passive intranasal transfer of anti‐influ‐
enza A IgA from the respiratory tract of mice immunized with live 
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influenza virus has been seen to provide protection in naive mice.43 
Accordingly, this protection was suppressed by the intranasal instil‐
lation of anti‐IgA,46 whereas it was not affected by treatment with 
anti‐IgM	or	anti‐IgG	antibodies.	This	result	supports	the	importance	
of IgA as a mediator of murine nasal anti‐influenza virus immunity in 
immunocompetent mice.47
Furthermore, several studies have found a higher level of cor‐
relation between the degree of protection and the antibody secre‐
tory level than serum antibodies both in mice48 and in humans.5
T‐LAIVs have been widely investigated in several clinical studies 
conducted on different age cohorts throughout the world.49 After 
influenza LAIV administration, as well as natural infection, sIgA are 
produced by memory B lymphocytes.
The immunogenicity, efficacy, or effectiveness of LAIVs in com‐
parison with IIVs has been analyzed in a number of studies.50‐54 A 
meta‐analysis of a number of investigations has shown that the LAIV 
has been less effective than IIV in general.55 However, individual 
studies with respect to mismatched vaccine strains or in children 
with underlying diseases such as asthma have shown a higher effi‐
ciency in comparison to IIV, for example, with respect to a circulat‐
ing variant (A/Sydney/H3N2) not present in the vaccine composition 
with an efficacy of 86% against this mismatched circulating strain51 
or in children affected by asthma53 or recurrent respiratory tract 
infections.52
A	more	recent	study	conducted	by	McLean54 reported a similar 
effectiveness	provided	by	a	Q‐LAIV	and	IIV	against	a	new	antigenic	
A(H3N2) variant, whereas a considerable higher protection was pro‐
vided	by	Q‐LAIV	compared	to	IIV	toward	a	drifted	influenza	B	strain.
Data obtained from the US reported an apparent lack of LAIV 
effectiveness in the 2015/2016 influenza season, especially toward 
A/H1N1 vaccine component. Such results have led the Advisory 
Committee on Immunization Practices (ACIP) not to use the LAIV 
in the US during the 2016/2017 seasons.56 Conversely from the 
observations reported in the US, a higher overall protection of the 
LAIV against laboratory‐confirmed infection with the A/H1N1 strain 
in comparison with IIV has been reported by the UK57 and Finland 
in the 2015/2016 season.58 For these reasons, LAIV use is closely 
monitored, but it is still recommended in these countries as well as 
in Norway, although the motives underlying this difference have not 
been elucidated yet.
The persistence of protective mucosal immune responses upon 
LAIV	immunization	has	been	investigated	in	several	studies.	Murphy	
and Clements45 found elevated levels of IgA that recognize HA, and 
reduced	levels	of	IgM	and	IgG,	in	nasal	washes	obtained	from	naïve	
children infected 2 weeks earlier by means of attenuated A viruses. 
In about 50% of the vaccinees, IgA and IgG in the nasal wash per‐
sisted	for	1	year.	Subsequent	studies	confirmed	the	persistence	of	
long‐term (at least 1 year) immunological memory following LAIV 
vaccination59 and of serum IgG.6 The longevity of local immune re‐
sponse up to a year indicates that the mucosal immune system is well 
developed also in young children.
Clinical Studies have shown that protection after LAIV vac‐
cination is correlated with local anti‐hemagglutinin (HA) IgA and 
anti‐neuraminidase antibodies in serum,6 whereas IgG antibodies 
are the main effectors in providing protection in the mucosal com‐
partments of human vaccinated with inactivated vaccines. These 
antibodies derive from plasma through a process of passive transu‐
dation following a concentration gradient between plasma and nasal 
IgG.60 The substantial differences in the presence of anti‐viral IgA 
and IgG antibodies in nasal washes or serum of individuals vacci‐
nated either with LAIV or with IIV indicate that these two vaccines 
are inducing fundamentally different immune responses resulting in 
different mechanisms of protection. Whereas the protection of the 
upper respiratory tract is provided mainly by IgA with IgG playing 
a minor part, the latter play a pivotal role in the protection of the 
lungs.6,60‐62 These differences in the specific immune responses 
have been confirmed by the recent meta‐analysis of the group of 
Wen et al62 which identified 191 and 195 differentially expressed 
genes in IIV and LAIV recipients, respectively. Whereas IIV induced 
the up‐regulation of genes associated with both the innate immune 
response and the humoral immune response, LAIV mostly elicited 
the innate immunity.
These data suggest that intranasal vaccinations may be the best 
choice to achieve immune responses which mimic natural infections 
by stimulating both systemic and mucosal immune response,63,64 
but without causing the signs and symptoms associated with influ‐
enza illness.49 Nowadays, intranasal vaccination against influenza is 
mainly made up through ca LAIVs.
However, other alternative ways used to induce mucosal immu‐
nity are currently available. These include the following: intranasal 
vaccinations using inactivated whole or split influenza vaccines,65,66 
sublingual administration of adjuvanted influenza vaccines,67 and 
novel types of LAIVs, for example, formulated by depleting the NS1 
gene. NS1 encodes for a non‐structural protein, resulting in attenu‐
ated viruses (DelNS1 viruses) unable to overcome the anti‐viral de‐
fenses of infected cells.37,68
4  | ELISA A SSAYS FOR THE 
DETERMINATION OF THE IGA CONTENT IN 
TEST SAMPLES
According to the type of influenza vaccine used and the route of 
administration, specific compartments of the human immune sys‐
tem are stimulated. A local mucosal immune response is elicited 
by natural infection or intranasal vaccination, while a systemic 
immune response develops after parenteral vaccination.69 As 
a	 consequence	 of	 stimulating	 different	 components	 of	 the	 im‐
mune system via mucosal or parenteral application of vaccines, 
the induction of serum hemagglutinin inhibition (HI) antibody ti‐
ters, which are still considered as the gold standard in assessing 
influenza vaccine immunogenicity, is generally lower after intra‐
nasal vaccination than those elicited by intramuscular vaccina‐
tion50; conversely, high levels of nasal IgA have been observed in 
recipients of LAIV.63 Of out a couple of laboratory tests that can 
be used to assess influenza antibody levels, the enzyme‐linked 
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immunosorbent assay (ELISA) is the most favorable one to meas‐
ure the mucosal immune responses.
Enzyme‐linked immunosorbent assay can accurately measure 
the concentrations of different classes of antibodies that are able to 
bind to influenza virions or purified HA proteins.70	Many	different	
protocols and standard kits are currently available on the market, 
but they are all based on the same principle. Generally, HA protein 
or whole influenza virus is pre‐adsorbed to the wells of an ELISA mi‐
croplate; different sample dilutions are then added, followed by the 
addition of the labeled secondary antibody, which is able to detect 
the immunoglobulins of interest. A colorimetric reaction is obtained 
upon the addition of a substrate. An important feature of the ELISA 
assay	 is	 that	 it	 can	measure	different	classes	of	 IgG,	 IgM,	and	 IgA	
present both in serum and in mucosal samples.71‐73
Currently, there are two main methods (Figure 2) of detecting 
influenza‐specific sIgA responses in nasal wash/swab and saliva 
samples.74,75 The two methods differ mainly in terms of the strategy 
adopted for the standardization of the samples to be analyzed, which 
precedes influenza‐specific IgA detection. Standardization of the 
mucosal samples is an important step, since the mucus and protein 
concentration of nasal washes varies widely between individuals, 
depending on several factors, such as age, history or concurrence of 
nasal disease, and aspiration efficacy.14 The first method described 
here is based on sample standardization according to the total con‐
tent of IgA present in each sample by using a standardized IgA ELISA 
kit,	whereas	 the	 second	method	 is	 based	on	 the	quantification	of	
total protein content through the bicinchoninic acid (BCA) assay 
(Figure 2).
4.1 | Influenza HA‐Specific IgA respect to Total IgA
This method is used to normalize the influenza‐specific IgA content 
of a sample through the total IgA content (Figure 2). The total IgA 
concentration in nasal wash/swab samples or saliva can easily be 
measured by using one of the many standardized ELISA kits avail‐
able on the market. Concerning influenza‐specific IgA detection, the 
procedure needs to be adapted due to the absence of a standard‐
ized human influenza‐specific IgA reference. The ELISA procedure 
in principle has been described elsewhere.73 In brief, ELISA plates 
are coated with an influenza antigen (preferably purified HA) and 
a capture antibody (anti‐human IgA). Samples and standards are 
added to the plate and incubated for 1‐2 hours at 37°C. The pres‐
ence and concentration of influenza‐specific IgA or total IgA is then 
determined by a color reaction applying an enzyme‐labeled second 
antibody against human IgA and the respective substrate followed 
by a read‐out in a conventional microtiter plate ELISA reader. The 
anti‐influenza IgA concentration is being extrapolated from the 
standard regression curve derived by diluting a human total IgA ref‐
erence	standard	of	known	starting	concentration.	As	a	consequence	
of this calculation, it is not possible to report the relative value of 
anti‐influenza IgA as µg; instead, it should be expressed as Unit/mL 
(U/mL), where 1 U corresponds to 1 µg of human IgA detected. It is 
F I G U R E  2   Principles of ELISA assays for the determination and standardization of the IgA content in test samples. Test samples include 
nasal	washes,	swabs,	or	saliva	samples.	Method	1:	Standardization	of	antigen‐specific	IgA	antibodies	against	total	IgA	(left	side,	yellow	
arrows).	Method	2:	Standardization	of	antigen‐specific	IgA	antibodies	against	total	protein	(right	side,	blue	and	red	arrows)	Variation	1:	high	
total protein content (>1 mg/mL; middle right side, blue arrows). Variation 2: low protein content (<1 mg/mL) or big differences of the total 
protein content of different test samples (rightmost side, red arrows)
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Total IgA
(Standardized IgA ELISA kit)
IgA-influenza specific by
using a standard curve
(Result as U/I)
IgA-influenza specific U/mL
Total IgA-influenza specific ug/mL
x 100 =
Result
expressed as
pure number
SAMPLES
Total protein measurement
(BCA assay)
[total protein]
<1 mg/mL
[total protein]
≥1 mg/mL
Standardization of
[total protein]
(e.g. 1 mg/mL)
Influenza-specific IgA ELISA
Read at 592
nm
Influenza-specific
IgA ELISA
Result expressed as titre
(e.g. 40, 80,160)
Total IgA
(Standardized IgA ELISA kit) (e.g. 280 ug/mL)
Titer/Total IgA = Result in U/mL
(e.g. 1280/280 = 4.57 U/ml)
Result expressed
as titer
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important to run multiple samples collected from the same subject 
at different time points in the same ELISA plate.14 According to this 
method, the value of influenza‐specific IgA normalized through the 
total IgA content will be expressed as “(Influenza‐Specific IgA (U/mL)/
Total IgA (µg/mL)) * 100.”.
4.2 | Influenza HA‐Specific IgA and Total Protein
The basis of this method is the measurement of the total protein 
content in the samples (Figure 2). The determination of influenza 
HA‐specific IgA with respect to total protein generally proves to be 
the best choice when a large number of samples have to be evalu‐
ated, since it is easy to use, sensitive, and rapid.75 Depending on the 
total protein concentration obtained, two different methods of cal‐
culations can be adopted (Figure 2).
The first method will be applied if the total protein of the sam‐
ples	is	higher	than	or	equal	to	1	mg/mL	by	standardization	of	nasal	
or saliva samples to a defined total protein content (Figure 2) which 
may vary according to the type of sample (nasal wash vs nasal swab 
vs saliva). The influenza‐specific IgA antibody titer is then calculated 
as the reciprocal of the highest dilution that yields an OD signal 
greater	than	or	equal	to	a	predefined	cutoff	value.	However,	since	
completely negative human nasal samples are usually not available, 
the	exact	calculation	of	a	cutoff	may	not	be	optimal	and	require	al‐
ternative approaches in the future.
One approach may be to use the “limit of blank” according to the 
following formula: “Average of background signals (ODBlank) plus 2 stan‐
dard deviations.”72 In this case, the cutoff value will be calculated with‐
out the need for a specific human sample; only ELISA reagents will be 
added to the coated plate together with the influenza antigen, and the 
background signal will be used to calculate the cutoff. An alternative 
possibility is the calculation of the cutoff value as the reciprocal of the 
highest dilution that shows an absorbance value >0.2 of the OD value 
after subtraction of the background as previously described.73
In the case of low total protein concentrations of the samples 
in general or of big differences of the total protein content of dif‐
ferent test samples, an alternative approach, combining the two 
approaches described above, can be used which is based on the es‐
timation of IgA content by using the ratio between the titer and the 
total IgA content (Figure 2).
5  | NEUTR ALIZING (NT) ANTIBODIES IN 
NA SAL WA SH/SWAB AND FUTURE A SSAYS
Some recent studies74,76 have assessed neutralization (NT) antibody 
levels in standardized nasal wash/swab samples after intranasal im‐
munization since NT antibodies are generally considered more spe‐
cific than hemagglutination inhibition (HI) antibody titers in children 
vaccinated with LAIVs. However, it has been shown in a previous 
pediatric study with LAIV that influenza virus–specific salivary IgA 
levels correlated with serum HI responses,76 although it is also dis‐
cussed that the measured HI titers may underestimate the protective 
potential of LAIVs.60,77 NT antibodies in serum samples are usually 
assessed	by	means	of	the	microneutralization	(MN),	either	CPE	(cy‐
topathic effect)‐based74 or ELISA‐based,37	 or	 the	 plaque‐reduction	
neutralization (PRNT) assay. In the present review, we focused on 
the	CPE‐based	MN	assay,	since	this	is	the	preferred	method	because	
of its simplicity of execution, its ability to evaluate large numbers of 
samples,	and	the	standardization	of	the	quantity	of	virus	used	in	the	
assay.78	Along	with	the	ELISA	sIgA	assay,	the	MN	assay	constitutes	
a valid approach to evaluate the immunogenicity of LAIVs, IIVs, or 
recombinant influenza vaccines (eg rHA) in inducing selective anti‐in‐
fluenza antibodies with influenza virus–neutralizing potential.
Beside classical ELISA‐based and NT assays specific anti‐HA in‐
fluenza antibodies, there are newer assays with increased precision 
and	sensitivity,	such	as	the	XMAP	(x	=	analyte	MAP	=	Multi‐analite	
profiling) technology adapted for Luminex‐based IgA assays.79,80 
The	XMAP	technology	is	a	serological	method	that	can	be	applied	to	
measure multiple proteins or antibodies in a single‐well reaction with 
high	accuracy	and	reproducibility.	The	Luminex	XMAP	technology	is	
based	on	 the	 combination	of	 different	well‐established	 techniques	
such as flow cytometry, carboxylated microspheres, laser, and tradi‐
tional chemistry. Briefly, specific nano‐magnetic beads can be coated 
with different purified proteins arising from the same pathogen or 
from different ones and then incubated with serum samples. Using 
specific biotinylated secondary antibody, the presence of antigen‐
specific	antibodies	in	sera	can	be	easily	measured	and	quantified	by	
a dedicated detection system (Luminex). Wang et al81 applied this 
novel method for the simultaneous detection of antibodies against 
the Newcastle disease and avian influenza virus and have shown that 
the	Luminex	XMAP‐based	assay	has	been	up	to	1024	times	more	sen‐
sitive for avian influenza virus antibody detection compared to the 
conventional	ELISA	assay.	The	minimal	 volume	of	 sample	 required,	
the cost reduction for multiple detection in comparison with the clas‐
sical methods, and the possibility to perform a rapid multiplexing in 
a single reaction are additional advantages of this new technology. 
However, these new generations of serological assays are not stan‐
dardized	and	require	further	studies	for	the	generation	of	validated	
and reproducible results. Currently, only the ELISA is a reliable and 
valuable approach to determine sIgA in various biological samples.
6  | CONCLUSIONS
Influenza vaccines elicit protective immunity before a new influenza 
virus variant is able to spread; they therefore constitute a primary 
protection tool. Although the main protective effectors against in‐
fluenza virus infection are CTLs, IgG, and IgA located in the respira‐
tory mucosa, most of the vaccines currently available are inactivated 
vaccines that are administered via parenteral injection, and which 
mostly promote serum IgG rather than mucosal IgA (rev. in82‐84). The 
importance of intranasally applied LAIVs is their ability to reproduce 
a natural infection without causing disease or virus transmission. 
They mimic the natural encounter with the antigen by activating the 
innate immune system and promoting antibody and T cell–mediated 
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immune responses. This type of vaccine can induce a broader im‐
mune response in children than intramuscular vaccines.31,85,86 
Furthermore, mucosal vaccines can elicit cross‐reactive antibodies 
in humans. However, the development of cross‐protective T lym‐
phocytes has been observed in animal models, but this has not yet 
confirmed in humans.85,86
An additional advantage of LAIVs is their consumer‐friendly nee‐
dle‐free intranasal application which represents a minimal invasive 
delivery method, and it is expected with higher production capaci‐
ties and a more widely distribution. For these reasons, its expanded 
use could increase the influenza vaccination coverage globally. 
Furthermore, it may represent a favorable approach for mass immu‐
nizations, especially in younger children since its application is not 
associated with pain.87
Although LAIVs have been on the global market for many years, 
no established correlates of protection for them are yet available.77 
Moreover,	previously	reported	discrepancies	of	efficacy	data	from	
Europe and the US further complicate the understanding of the 
immune response elicited by LAIV.77 Despite these complications, 
great efforts have been made in the recent years to develop novel in‐
tranasally administered vaccines to promote influenza virus‐specific 
sIgA,30,88 which, as has been widely reported, provide broader pro‐
tection than serum IgG. A robust mucosal response is fundamental in 
order to protect both the single individual and the entire population 
by preventing transmission of the virus to susceptible subjects.89 
Notably, the use of the ELISA assay for IgA detection could play a 
major role in the evaluation of vaccine efficacy or effectiveness in 
the field, as currently influenza vaccine efficacy is traditionally as‐
sessed by means of serological assays that detect influenza‐specific 
serum antibodies induced by the vaccine itself. However, these as‐
says cannot be properly applied to intranasal vaccines, which mainly 
induce local immune responses (rev. in90).
In conclusion, the measurement of sIgA in mucosal secretions for 
the evaluation of influenza vaccine efficacy or effectiveness and, in 
addition, also of the effectiveness of vaccines against other respi‐
ratory virus infections of the respiratory mucosae, is arousing great 
interest and may constitute a valuable asset.
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